Vaccine News and Research

Latest Vaccine News and Research

COVID-19 vaccination in New York City reduces hospital admissions and deaths

A new study, released as a preprint on the medRxiv* server, shows how the successful rollout of effective COVID-19 vaccines in this metropolis led to the dramatic reduction in the number of cases with moderate to severe coronavirus disease 2019 (COVID-19) and curbed COVID-19-related mortality.

20 Jul 2021

NIH grant supports WVU-led team to increase COVID-19 testing among underserved populations

Not all West Virginians have the luxury of popping into a health clinic on a whim to get tested for COVID-19.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Exhausted T cells linked to increased risk of COVID-19 mortality

New research led by Nadia R. Roan of Gladstone Institutes and the University of California, San Francisco, finds a correlation between high numbers of inflammatory CXCR4+ T cells and regulatory T cells specific to SARS-CoV-2 and dying from infection. In contrast, people who recovered from severe COVID-19 illness were more likely to have many SARS-CoV-2-specific T cells that perform homeostatic proliferation.

20 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.

19 Jul 2021

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine.

19 Jul 2021

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

A single-center, cross-sectional epidemiological survey conducted in Israel has recently pointed out that antibodies induced by natural SARS-CoV-2 infection in children start declining just after 4 months of acute infection. However, their seropositivity rates are not impacted by school reopening. The study has recently been published in the journal Acta Paediatrica.

19 Jul 2021

Grab your mask and notepad, we’re headed back to California’s state Capitol

The best part about returning to the pandemic-besieged state Capitol is that the elected officials are so unused to seeing us reporters after more than a year that some are occasionally extra chatty. The bad part is that the masks make it harder to eavesdrop on the rest of them.

19 Jul 2021

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

A team of scientists from the United States has recently compared the epitope-specific T cell response after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination in both naïve and previously infected individuals.

19 Jul 2021

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

A new study has been published on the bioRxiv* preprint server, which focuses on the mechanism behind the binding of SARS-CoV-2 with the host receptor, using a molecular dynamics approach. The authors of this study aim to highlight the role of glycans in initiating the interaction between S and ACE2.

19 Jul 2021

Patient's case report reveals link between Bell’s palsy and Pfizer-BioNTech vaccine

The case of a patient who experienced two facial palsies – one after the first and another after the second dose of the Pfizer-BioNTech COVID-19 vaccine – strongly suggests that Bell’s palsy (facial nerve palsy of unknown cause) is linked to the Pfizer-BioNTech vaccine, doctors write in the journal BMJ Case Reports.

19 Jul 2021

Plant-based vaccines for COVID-19 and other viruses

A review published in the journal Vaccines, explored the history and current status of plant-produced vaccine candidates against enveloped viruses, focusing on virus-like particles (VLPs), which mimic authentic viral structures without containing infectious genetic material.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Vaccine News and Research

Latest Vaccine News and Research

COVID-19 vaccination in New York City reduces hospital admissions and deaths

NIH grant supports WVU-led team to increase COVID-19 testing among underserved populations

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Exhausted T cells linked to increased risk of COVID-19 mortality

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Study: Second dose of COVID-19 vaccine induces a powerful boost to the immune system

Study suggests children develop short-term humoral immunity following SARS-CoV-2 infection

Grab your mask and notepad, we’re headed back to California’s state Capitol

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

Patient's case report reveals link between Bell’s palsy and Pfizer-BioNTech vaccine

Plant-based vaccines for COVID-19 and other viruses

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

How do immunocompromised patients respond to COVID-19 vaccines?

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in